From: The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
Characteristic | Tiotropium Respimat® 5 μg (n = 461) | Tiotropium Respimat® 2.5 μg (n = 464) | Tiotropium HandiHaler® 18 μg (n = 445) |
---|---|---|---|
Male sex, % | 63.6 | 62.9 | 59.3 |
Age, years | 65.3 ± 9.1 | 65.6 ± 9.1 | 65.8 ± 8.4 |
Current smoker, % | 39.9 | 40.1 | 33.3 |
Smoking history, pack-year | 49.7 ± 27.7 | 51.0 ± 28.6 | 50.1 ± 28.9 |
FEV1, L | 1.256 ± 0.445 | 1.215 ± 0.479 | 1.203 ± 0.489 |
FEV1, % predicteda | 49.31 ± 12.99 | 48.26 ± 13.47 | 48.28 ± 13.63 |
FVC, L | 2.555 ± 0.743 | 2.517 ± 0.796 | 2.482 ± 0.858 |
FEV1/FVC ratio, % | 49.5 ± 11.0 | 48.4 ± 11.5 | 48.6 ± 11.2 |
GOLD Stage, % | |||
FEV1/FVC ≥70 % | 1.3 | 1.7 | 2.0 |
I | 0.7 | 0.0 | 0.2 |
II | 49.2 | 46.1 | 42.9 |
III | 40.8 | 42.0 | 44.3 |
IV | 8.0 | 10.1 | 10.3 |
Any respiratory medication, % | 95.7 | 95.0 | 97.8 |
Anticholinergics | 69.2 | 69.6 | 69.0 |
LABAb | 66.6 | 66.2 | 67.9 |
ICSb | 60.1 | 61.2 | 62.0 |